Chiome Bioscience Inc. (4583)

Overview

Chiome Bioscience Inc., founded in 2005 and based in Tokyo, Japan, operates globally in the domain of drug discovery technology platform research and development. The company’s operations are diversified into two main segments: the Drug Discovery Business and the Drug Discovery Support Business. Not only does Chiome Bioscience innovate in the development of monoclonal antibodies with its proprietary ADLib System but also provides a suite of services ranging from protein expression to stable cell line generation. Serving an array of clients including universities, research institutions, and pharmaceutical companies, Chiome Bioscience is at the forefront of offering cutting-edge solutions for drug discovery and development.

Products and Services

• ADLib System: A revolutionary monoclonal antibody generating system designed for drug discovery and development, enabling rapid and efficient antibody generation.
• Human ADLib System: Provides chicken antibody gene conversion to humanized antibodies, facilitating the creation of more compatible therapeutic agents.
• Protein Expression and Purification Services: Offers tailored services for the expression and purification of proteins critical for research and pharmaceutical development.
• Stable Cell Line Generation Services: Specializes in generating stable cell lines for recombinant protein and antibody production, aiding in consistent and reliable research outcomes.
• Antibody Generation Services: Utilizes the ADLib system or B cell cloning techniques for bespoke antibody generation, catering to specific research and therapeutic needs.

In its robust pipeline, Chiome Bioscience has several noteworthy drug candidates in various development stages:

• ADCT-701: An anti-dlk1 antibody targeting liver cancer, currently in phase 1 trial.
• CBA-1205: An afucosylated anti-dlk1 antibody for the treatment of liver cancer, lung cancer, and neuroblastoma, also under phase 1 trial.
• CBA-1535: Targets malignant mesothelioma, small and non-small cell lung cancer, and breast cancer (TNBC) with an anti 5T4/WAIF1 antibody, in phase 1 trial.
• Preclinical Studies: The pipeline further includes preclinical studies like LIV-2008/2008b, an anti-TROP-2 antibody for TNBC, lung, and colorectal cancer; BMAA, an anti-semphorin3a antibody; PCDC, an anti-CDCP1 antibody; PTRY, a 5T4/CD3/PD-L1 antibody; and PFKR, an anti-CX3CR1 antibody for secondary progressive multiple sclerosis.